BidaskClub downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a report released on Thursday.
A number of other research analysts also recently weighed in on the company. Zacks Investment Research downgraded ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, January 2nd. Canaccord Genuity set a $77.00 price objective on ANI Pharmaceuticals and gave the company a buy rating in a research note on Friday, December 29th. ValuEngine downgraded ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, December 20th. Finally, TheStreet raised ANI Pharmaceuticals from a c+ rating to a b rating in a research note on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $71.00.
ANI Pharmaceuticals (NASDAQ:ANIP) opened at $56.98 on Thursday. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. ANI Pharmaceuticals has a one year low of $42.23 and a one year high of $74.70. The firm has a market capitalization of $663.99, a P/E ratio of 89.03 and a beta of 2.79.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3222242/ani-pharmaceuticals-anip-cut-to-sell-at-bidaskclub.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.